Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.

Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.

Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. doi: 10.1158/1078-0432.CCR-19-0448. Epub 2019 Aug 13.

PMID:
31409614
2.

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.

Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, Liu J, Dhaneshwar A, DePeaux K, Gowaski MR, Bailey D, Regan SN, Ivanova E, Ferrante C, English JM, Khosla A, Beck AH, Rytlewski JA, Sanders C, Laquerre S, Bittinger MA, Kirschmeier PT, Packman K, Janne PA, Moy C, Wong KK, Verona RI, Lorenzi MV.

Cancer Immunol Res. 2019 Sep;7(9):1457-1471. doi: 10.1158/2326-6066.CIR-18-0595. Epub 2019 Jul 22.

PMID:
31331945
3.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

PMID:
30880072
4.

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.

Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, Wu M, Malladi VS, Huang W, Walker W, Palakurthi S, Dranoff G, Hammerman PS, Pecot CV, Wong KK, Akbay EA.

J Immunother Cancer. 2019 Feb 6;7(1):32. doi: 10.1186/s40425-019-0504-5.

5.

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.

Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS.

Mol Cancer Ther. 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24.

PMID:
30679390
6.

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.

Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, Qi J, Shapiro GI, Liu JF, Matulonis UA, Lin CY, Konstantinopoulos PA, Gray NS.

Elife. 2018 Nov 13;7. pii: e39030. doi: 10.7554/eLife.39030.

7.

Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability.

Vaidya B, Shukla SK, Kolluru S, Huen M, Mulla N, Mehra N, Kanabar D, Palakurthi S, Ayehunie S, Muth A, Gupta V.

Carbohydr Polym. 2019 Jan 15;204:68-77. doi: 10.1016/j.carbpol.2018.09.080. Epub 2018 Oct 4.

PMID:
30366544
8.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.

Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2.

PMID:
30072474
9.

Development and Evaluation of Talazoparib Nanoemulsion for Systemic Therapy of BRCA1-mutant Cancer.

Mehra NK, Tekmal RR, Palakurthi S.

Anticancer Res. 2018 Aug;38(8):4493-4503. doi: 10.21873/anticanres.12753.

PMID:
30061215
10.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

11.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

12.

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.

Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS.

Nat Commun. 2017 Aug 28;8(1):365. doi: 10.1038/s41467-017-00263-7.

13.
14.

Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Zhang H, Brainson CF, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Alan Diehl J, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.

Nat Commun. 2017 Jun 9;8:15901. doi: 10.1038/ncomms15901.

15.

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Zhang H, Fillmore Brainson C, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Diehl JA, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.

Nat Commun. 2017 Apr 7;8:14922. doi: 10.1038/ncomms14922. Erratum in: Nat Commun. 2017 Jun 09;8:15901.

16.

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.

Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.

17.

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.

Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R.

Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29.

18.

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Jänne PA, Eck MJ.

Nature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25.

19.

Safety and toxicity of nanomaterials for ocular drug delivery applications.

Mehra NK, Cai D, Kuo L, Hein T, Palakurthi S.

Nanotoxicology. 2016 Sep;10(7):836-60. doi: 10.3109/17435390.2016.1153165. Epub 2016 Mar 30. Review.

PMID:
27027670
20.

Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.

Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS.

Sci Transl Med. 2016 Mar 9;8(329):329ra34. doi: 10.1126/scitranslmed.aad5653.

21.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS.

Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501.

22.

Recent Advances in Topical Ocular Drug Delivery.

Yellepeddi VK, Palakurthi S.

J Ocul Pharmacol Ther. 2016 Mar;32(2):67-82. doi: 10.1089/jop.2015.0047. Epub 2015 Dec 14. Review.

PMID:
26666398
23.

Interactions between carbon nanotubes and bioactives: a drug delivery perspective.

Mehra NK, Palakurthi S.

Drug Discov Today. 2016 Apr;21(4):585-97. doi: 10.1016/j.drudis.2015.11.011. Epub 2015 Nov 30. Review.

PMID:
26657088
24.

Challenges in SN38 drug delivery: current success and future directions.

Palakurthi S.

Expert Opin Drug Deliv. 2015;12(12):1911-21. doi: 10.1517/17425247.2015.1070142. Epub 2015 Jul 24. Review.

PMID:
26206312
26.

Nanomedicine scale-up technologies: feasibilities and challenges.

Paliwal R, Babu RJ, Palakurthi S.

AAPS PharmSciTech. 2014 Dec;15(6):1527-34. doi: 10.1208/s12249-014-0177-9. Epub 2014 Jul 22. Review.

27.

Zein in controlled drug delivery and tissue engineering.

Paliwal R, Palakurthi S.

J Control Release. 2014 Sep 10;189:108-22. doi: 10.1016/j.jconrel.2014.06.036. Epub 2014 Jun 30. Review.

PMID:
24993426
28.

SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.

Vangara KK, Ali HI, Lu D, Liu JL, Kolluru S, Palakurthi S.

AAPS PharmSciTech. 2014 Apr;15(2):472-82. doi: 10.1208/s12249-013-0068-5. Epub 2014 Jan 30.

29.

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D.

Blood. 2014 Feb 6;123(6):905-13. doi: 10.1182/blood-2013-04-495366. Epub 2013 Dec 20.

30.

Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.

Vangara KK, Liu JL, Palakurthi S.

Anticancer Res. 2013 Jun;33(6):2425-34.

PMID:
23749891
31.

Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.

Vasbinder MM, Aquila B, Augustin M, Chen H, Cheung T, Cook D, Drew L, Fauber BP, Glossop S, Grondine M, Hennessy E, Johannes J, Lee S, Lyne P, Mörtl M, Omer C, Palakurthi S, Pontz T, Read J, Sha L, Shen M, Steinbacher S, Wang H, Wu A, Ye M.

J Med Chem. 2013 Mar 14;56(5):1996-2015. doi: 10.1021/jm301658d. Epub 2013 Feb 27.

PMID:
23398453
32.

Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.

Yellepeddi VK, Vangara KK, Kumar A, Palakurthi S.

Anticancer Res. 2012 Sep;32(9):3651-8.

PMID:
22993302
33.

Differential expression of caveolin-1 and caveolin-3: potential marker for cardiac toxicity subsequent to chronic ozone inhalation.

Sethi R, Manchanda S, Perepu RS, Kumar A, Garcia C, Kennedy RH, Palakurthi S, Dostal D.

Mol Cell Biochem. 2012 Oct;369(1-2):9-15. doi: 10.1007/s11010-012-1363-2. Epub 2012 Jul 1.

PMID:
22752385
34.

Essential role of TAK1 in regulating mantle cell lymphoma survival.

Buglio D, Palakurthi S, Byth K, Vega F, Toader D, Saeh J, Neelapu SS, Younes A.

Blood. 2012 Jul 12;120(2):347-55. doi: 10.1182/blood-2011-07-369397. Epub 2012 May 30. Erratum in: Blood. 2014 Jul 17;124(3):463.

35.

Recent trends in cancer drug resistance reversal strategies using nanoparticles.

Palakurthi S, Yellepeddi VK, Vangara KK.

Expert Opin Drug Deliv. 2012 Mar;9(3):287-301. doi: 10.1517/17425247.2012.665365. Review.

PMID:
22339554
36.

Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT.

Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK, Palakurthi S.

Anticancer Res. 2011 Mar;31(3):897-906.

PMID:
21498711
37.

Mechanism of gene transfection by polyamidoamine (PAMAM) dendrimers modified with ornithine residues.

Kumar A, Yellepeddi VK, Vangara KK, Strychar KB, Palakurthi S.

J Drug Target. 2011 Nov;19(9):770-80. doi: 10.3109/1061186X.2011.568061. Epub 2011 Apr 4.

PMID:
21457075
38.

Enhanced gene transfection efficiency by polyamidoamine (PAMAM) dendrimers modified with ornithine residues.

Kumar A, Yellepeddi VK, Davies GE, Strychar KB, Palakurthi S.

Int J Pharm. 2010 Jun 15;392(1-2):294-303. doi: 10.1016/j.ijpharm.2010.03.054. Epub 2010 Apr 2.

PMID:
20363307
39.
40.

Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications.

Yellepeddi VK, Kumar A, Palakurthi S.

Expert Opin Drug Deliv. 2009 Aug;6(8):835-50. doi: 10.1517/17425240903061251. Review.

PMID:
19637972
41.

Increase in thiol oxidative stress via glutathione reductase inhibition as a novel approach to enhance cancer sensitivity to X-ray irradiation.

Zhao Y, Seefeldt T, Chen W, Carlson L, Stoebner A, Hanson S, Foll R, Matthees DP, Palakurthi S, Guan X.

Free Radic Biol Med. 2009 Jul 15;47(2):176-83. doi: 10.1016/j.freeradbiomed.2009.04.022. Epub 2009 Apr 24.

42.

Transport of surface engineered polyamidoamine (PAMAM) dendrimers across IPEC-J2 cell monolayers.

Pisal DS, Yellepeddi VK, Kumar A, Palakurthi S.

Drug Deliv. 2008 Nov;15(8):515-22. doi: 10.1080/10717540802321826 .

PMID:
18720134
43.

Target specificity of 188Re-labeled B27.1 monoclonal antibodies to ovarian cancer cells in vivo.

Palakurthi S, Wilson J, McQuarrie SA, Suresh MR, Mercer JR, Miller GG.

In Vivo. 2008 May-Jun;22(3):321-6.

44.
45.

Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers.

Pisal DS, Yellepeddi VK, Kumar A, Kaushik RS, Hildreth MB, Guan X, Palakurthi S.

Int J Pharm. 2008 Feb 28;350(1-2):113-21. Epub 2007 Aug 26.

46.

Biodisposition of PEG-coated lipid microspheres of indomethacin in arthritic rats.

Palakurthi S, Vyas SP, Diwan PV.

Int J Pharm. 2005 Feb 16;290(1-2):55-62. Epub 2005 Jan 7.

PMID:
15664130
47.
48.

Biodistribution of liposomes of terbutaline sulfate in guinea pigs.

Palakurthi S, Govardhanachary M, Vyas SP, Diwan PV.

Drug Dev Ind Pharm. 2000 Oct;26(10):1099-105.

PMID:
11028225
49.

Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid.

Palakurthi SS, Flückiger R, Aktas H, Changolkar AK, Shahsafaei A, Harneit S, Kilic E, Halperin JA.

Cancer Res. 2000 Jun 1;60(11):2919-25.

50.

Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole.

Aktas H, Flückiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA.

Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8280-5.

Supplemental Content

Loading ...
Support Center